Logo image of KRBP

KIROMIC BIOPHARMA INC (KRBP) Stock Fundamental Analysis

NASDAQ:KRBP - Nasdaq - US4976342042 - Common Stock - Currency: USD

1.45  -0.13 (-8.23%)

After market: 0.6931 -0.76 (-52.2%)

Fundamental Rating

0

Overall KRBP gets a fundamental rating of 0 out of 10. We evaluated KRBP against 557 industry peers in the Biotechnology industry. KRBP has a bad profitability rating. Also its financial health evaluation is rather negative. KRBP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

KRBP had negative earnings in the past year.
KRBP had a negative operating cash flow in the past year.
In the past 5 years KRBP always reported negative net income.
In the past 5 years KRBP always reported negative operating cash flow.
KRBP Yearly Net Income VS EBIT VS OCF VS FCFKRBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

KRBP has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KRBP Yearly ROA, ROE, ROICKRBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 0 500 -500 -1K

1.3 Margins

KRBP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KRBP Yearly Profit, Operating, Gross MarginsKRBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for KRBP has been increased compared to 1 year ago.
KRBP has a worse debt/assets ratio than last year.
KRBP Yearly Shares OutstandingKRBP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 200K 400K 600K
KRBP Yearly Total Debt VS Total AssetsKRBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 10M 20M 30M

2.2 Solvency

KRBP has an Altman-Z score of -18.78. This is a bad value and indicates that KRBP is not financially healthy and even has some risk of bankruptcy.
KRBP has a Altman-Z score of -18.78. This is amonst the worse of the industry: KRBP underperforms 87.48% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -18.78
ROIC/WACCN/A
WACCN/A
KRBP Yearly LT Debt VS Equity VS FCFKRBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 0.25 indicates that KRBP may have some problems paying its short term obligations.
The Current ratio of KRBP (0.25) is worse than 97.53% of its industry peers.
A Quick Ratio of 0.25 indicates that KRBP may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.25, KRBP is doing worse than 97.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.25
Quick Ratio 0.25
KRBP Yearly Current Assets VS Current LiabilitesKRBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M

More info and screens

0

3. Growth

3.1 Past

KRBP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.87%, which is quite impressive.
EPS 1Y (TTM)24.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.48%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KRBP Yearly EPS VS EstimatesKRBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KRBP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KRBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KRBP Price Earnings VS Forward Price EarningsKRBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KRBP Per share dataKRBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -10 -20 -30 -40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KRBP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KIROMIC BIOPHARMA INC

NASDAQ:KRBP (9/13/2023, 8:21:06 PM)

After market: 0.6931 -0.76 (-52.2%)

1.45

-0.13 (-8.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-10 2023-08-10
Earnings (Next)11-13 2023-11-13/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners256.72%
Ins Owner Change0%
Market Cap1.71M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-47.46
EYN/A
EPS(NY)-1.58
Fwd EYN/A
FCF(TTM)-17.61
FCFYN/A
OCF(TTM)-17.67
OCFYN/A
SpS0
BVpS-5.35
TBVpS-5.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.64%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.25
Quick Ratio 0.25
Altman-Z -18.78
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)474.78%
Cap/Depr(5y)386.54%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.38%
EPS Next Y33.48%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.88%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-28.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.88%
OCF growth 3YN/A
OCF growth 5YN/A